Зуд и другие проявления кожной токсичности у пациентов с меланомой на фоне терапии ингибиторами BRAF и MEK: обзор клинических рекомендаций по тактике ведения

Abstract

Targeted therapy of melanoma with BRAF and MEK inhibitors has become a breakthrough in the treatment of this aggressive tumor. At the same time, long-term use of these effective drugs is often limited by the development of severe adverse events, among which skin toxicity symptoms are of special importance. Therefore, this article presents the spectrum of manifestations of skin toxicity of combined targeted therapy with BRAF and MEK inhibitors using the combination of vemurafenib and cobimetinib as an example: pruritus, maculopapular and papulopustular rash, photosensitivity, alopecia, skin neoplasms. The principles of diagnostics are discussed, algorithms for prescribing external and systemic therapy are presented, taking into account the severity of damage to the skin and its appendages.